GBT Overview
Upcoming Projects (GBT)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (GBT)
-
Understanding Physicians' Experience with Oxbryta for Sickle Cell Anemia Patients - A Prescriber's View
Ticker: GBT
Executed On: Nov 20, 2020 at 10:30 AM EST -
Checking in on the Voxelator Launch With A Sickle Cell Expert (2 week delayed release to library)
Ticker: GBT
Executed On: Feb 12, 2020 at 09:15 AM EST -
A Third Take: A Community Doctor's Perspective on Sickle Cell Disease & Voxelotor's Potential (GBT440)
Ticker: GBT
Executed On: Dec 18, 2019 at 07:00 PM EST -
A Second View: A Community Doctor's Perspective on Sickle Cell Disease & Voxelotor's Potential (GBT440)
Ticker: GBT
Executed On: Dec 18, 2019 at 04:00 PM EST -
A Community Doctor's Perspective on Sickle Cell Disease & Voxelotor's Potential (GBT440)
Ticker: GBT
Executed On: Dec 18, 2019 at 03:00 PM EST -
Discussing Rivipansel in Sickle Cell Disease and the Published Phase 2 Data.
Tickers: GLYC, GBT
Executed On: Jul 16, 2019 at 02:30 PM EDT -
Discussing BLUE’s new SCD results from ASH 2018 and the sickle cell treatment landscape.
Tickers: BLUE, GBT
Executed On: Dec 14, 2018 at 10:00 AM EST -
A 7th Perspective: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, Emmaus Life Sciences
Executed On: Aug 10, 2018 at 02:45 PM EDT -
A 6th View: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, Emmaus Life Sciences
Executed On: Aug 10, 2018 at 12:00 PM EDT -
A 5th View: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, Emmaus Life Sciences
Executed On: Aug 08, 2018 at 08:00 AM EDT -
A 4th View: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, BLUE
Executed On: Jul 11, 2018 at 04:00 PM EDT -
A 3rd View: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, BLUE
Executed On: Jul 02, 2018 at 03:00 PM EDT -
A 2nd Look: Discussing this week's Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, BLUE
Executed On: Jun 29, 2018 at 01:00 PM EDT -
FLASH CALL: Discussing this morning's Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)
Tickers: GBT, BLUE
Executed On: Jun 27, 2018 at 04:00 PM EDT -
Discussing the latest GBT Sickle Cell Trial for Voxelotor (Previously GBT440) and its market potential
Tickers: GBT, BLUE
Executed On: Apr 25, 2018 at 01:00 PM EDT -
What's the potential of Global Blood Therapeutics’ Voxelotor (GBT440) in sickle cell disease after data released at ASH 2017
Ticker: GBT
Executed On: Dec 21, 2017 at 01:10 PM EST
Upcoming & Overdue Catalysts (GBT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (GBT)
-
Phase 3 Voxelotor HOPE Part A
Ticker: GBT
Occurred on: Jun 27, 2018 -
Top-line data due 1H 2019 for Global Blood Therapeutics'(GBT) GBT440 - HOPE Sickle cell disease in adults
Ticker: GBT
Occurred on: Jun 27, 2018 -
Upcoming Presentations of GBT440 Data in patients with the HBSC genotype sickle cell expected at ASCAT and SCDAA conferences
Ticker: GBT
Occurred on: Oct 28, 2017 -
FDA Approves Design for Global Blood's (GBT) Phase 3 Hope Trial Evaluating GBT440 in Sickle Cell Disease
Ticker: GBT
Occurred on: Oct 24, 2016 -
Global Blood Therapeutics Receives FDA Orphan Drug Designation for GBT440 in Sickle Cell Disease
Ticker: GBT
Occurred on: Dec 31, 2015
Strategic Initiatives (GBT)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
